These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11235628)

  • 41. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system.
    Wise S; Chien J; Yeo K; Richardson C
    Diabet Med; 2006 May; 23(5):510-5. PubMed ID: 16681559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diabetes: a struggle for sugar control.
    Lavalle A
    School Nurse News; 2002 Mar; 19(2):47. PubMed ID: 11979662
    [No Abstract]   [Full Text] [Related]  

  • 43. Type-1 diabetes mellitus with insufficient serum immunoreactive insulin elevation after subcutaneous NPH-insulin injection.
    Davidson MB
    Diabetes Res Clin Pract; 2004 Jun; 64(3):229. PubMed ID: 15126013
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of insulin antibodies and their kinetic characteristics on plasma free insulin dynamics in patients with diabetes mellitus.
    Van Haeften TW; Bolli GB; Dimitriadis GD; Gottesman IS; Horwitz DL; Gerich JE
    Metabolism; 1986 Jul; 35(7):649-56. PubMed ID: 3523119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A model for multiple subcutaneous insulin injections developed from individual diabetic patient data.
    Puckett WR; Lightfoot EN
    Am J Physiol; 1995 Dec; 269(6 Pt 1):E1115-24. PubMed ID: 8572205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Flexibility and effectiveness of diabetes therapy].
    Krankenpfl J; 2005; 43(1-3):62. PubMed ID: 15912849
    [No Abstract]   [Full Text] [Related]  

  • 47. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration.
    Quellhorst E
    J Am Soc Nephrol; 2002 Jan; 13 Suppl 1():S92-6. PubMed ID: 11792768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin formulation and delivery.
    Brange J; Langkjaer L
    Pharm Biotechnol; 1997; 10():343-409. PubMed ID: 9160379
    [No Abstract]   [Full Text] [Related]  

  • 49. Insulin strategies for managing inpatient and outpatient hyperglycemia and diabetes.
    Moghissi ES
    Mt Sinai J Med; 2008 Dec; 75(6):558-66. PubMed ID: 19021195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship of adiposity to subclinical atherosclerosis in obese patients with type 2 diabetes.
    Hegazi RA; Sutton-Tyrrell K; Evans RW; Kuller LH; Belle S; Yamamoto M; Edmundowicz D; Kelley DE
    Obes Res; 2003 Dec; 11(12):1597-605. PubMed ID: 14694226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alternative delivery routes: inhaled insulin.
    Heinemann L
    Diabetes Nutr Metab; 2002 Dec; 15(6):417-22. PubMed ID: 12678460
    [No Abstract]   [Full Text] [Related]  

  • 52. Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control.
    Radermecker RP; Renard E; Scheen AJ
    Diabetes Metab Res Rev; 2009 Sep; 25(6):491-501. PubMed ID: 19496088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Long-acting insulin analog, glargine, in the treatment of type 1 diabetes].
    Tuomi T
    Duodecim; 2004; 120(1):88-92. PubMed ID: 14976814
    [No Abstract]   [Full Text] [Related]  

  • 54. Insulin degradation in serum of a patient with apparent insulin resistance.
    Misbin RI; Almira EC; Cleman MW
    J Clin Endocrinol Metab; 1981 Feb; 52(2):177-80. PubMed ID: 7007401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Insulin and the giving of insulin injections].
    Schmidt T
    Krankenpflege (Frankf); 1985; 39(7-8):247-9. PubMed ID: 3932760
    [No Abstract]   [Full Text] [Related]  

  • 56. [Insulin therapy in the type 2 obese diabetic patient. Supplementing the deficit].
    Matthaei S; Häring HU
    MMW Fortschr Med; 2001 May; 143(21):35-7. PubMed ID: 11420829
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus.
    Crasto W; Jarvis J; Hackett E; Nayyar V; McNally PG; Davies MJ; Lawrence IG
    Postgrad Med J; 2009 Apr; 85(1002):219-22. PubMed ID: 19417173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Substantial blood glucose control differences at Swedish surgery departments. Common guidelines required].
    Escher C; Rolandsson O; Sandström H
    Lakartidningen; 2006 Nov 29-Dec 5; 103(48):3811-4. PubMed ID: 17212244
    [No Abstract]   [Full Text] [Related]  

  • 59. Bioavailability of highly purified bovine ultralente insulin.
    Home PD; Hanning I; Capaldo B; Alberti KG
    Diabetes Care; 1983; 6(2):210. PubMed ID: 6343027
    [No Abstract]   [Full Text] [Related]  

  • 60. [The Durasuline].
    Journ Annu Diabetol Hotel Dieu; 1969; 10():415-6. PubMed ID: 5377000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.